Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.

Veröffentlicht vonadmin

Greil, R; Tedeschi, A; Moreno, C; Anz, B; Larratt, L; Simkovic, M; Gill, D; Gribben, JG; Flinn, IW; Wang, ZY; Cheung, LWK; Nguyen, AN; Zhou, C; Styles, L; Demirkan, F

View this publication in the PUBMED database